SCHEMBL25368100

SCHEMBL25368100

CC(C)N1CC2(CCN(c3ccc(-c4ccc5nc(-c6ccc(S(C)(=O)=O)cc6)n(C)c5n4)cc3)CC2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.37
▸ PTGS2 P35354 9/20 0.37
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ GRM2 Q14416 1/20 0.36
▸ JAK2 O60674 2/20 0.35
▸ JAK3 P52333 2/20 0.35
▸ PTK2 Q05397 2/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ PTGS1 P23219 3/20 0.35
▸ TNF P01375 1/20 0.35
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30557460 1.00 HRH3 (0.37) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL25362939 0.93 PTGS2 (0.40) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL30557586 0.93 PTGS2 (0.40) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL30557377 0.90 HRH3 (0.47) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL25366146 0.90 HRH3 (0.47) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL25364691 0.89 CYP2D6 (0.40) PTGS2MAOAMAOBGRM2JAK2
SCHEMBL30557474 0.89 CYP2D6 (0.40) PTGS2MAOAMAOBGRM2JAK2
SCHEMBL25368054 0.84 GRM2 (0.42) PTGS2MAOAMAOBGRM2JAK2
SCHEMBL30557471 0.84 GRM2 (0.42) PTGS2MAOAMAOBGRM2JAK2
SCHEMBL25366291 0.83 GPR119 (0.39) HRH3PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-05 — — US disclosed
WO-2023159154-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 TLR9, TLR3, TLR1 HRH3 180/4885PTGS2 666/4885MAOA 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback